A share price of Ascendis Pharma A/S ADR [ASND] is currently trading at $212.11, down -0.53%. An important factor to consider is whether the stock is rising or falling in short-term value. The ASND shares have gain 7.87% over the last week, with a monthly amount glided 3.77%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ascendis Pharma A/S ADR [NASDAQ: ASND] stock has seen the most recent analyst activity on November 18, 2025, when Wolfe Research initiated its Peer Perform rating and assigned the stock a price target of $255. Previously, Raymond James started tracking the stock with Strong Buy rating on October 17, 2025, and set its price target to $271. Morgan Stanley upgraded its rating to an Overweight but stick to its price target of $250 on May 05, 2025. RBC Capital Mkts initiated its recommendation with an Outperform and recommended $205 as its price target on April 16, 2025. UBS started tracking with a Buy rating for this stock on January 07, 2025, and assigned it a price target of $196. In a note dated September 05, 2024, Oppenheimer upgraded an Outperform rating on this stock but restated the target price of $180.
Ascendis Pharma A/S ADR experienced fluctuations in its stock price throughout the past year between $118.03 and $229.94. Currently, Wall Street analysts expect the stock to reach $246.67 within the next 12 months. Ascendis Pharma A/S ADR [NASDAQ: ASND] shares were valued at $212.11 at the most recent close of the market. An investor can expect a potential return of 16.29% based on the average ASND price forecast.
Analyzing the ASND fundamentals
Trailing Twelve Months sales for Ascendis Pharma A/S ADR [NASDAQ:ASND] were 720.68M which represents 292.94% growth. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -0.52%, Pretax Profit Margin comes in at -0.54%, and Net Profit Margin reading is -0.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is 1.87 and Total Capital is -1.66. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-4.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 206.90 points at the first support level, and at 201.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 214.94, and for the 2nd resistance point, it is at 217.77.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ascendis Pharma A/S ADR [NASDAQ:ASND] is 1.03. On the other hand, the Quick Ratio is 0.73, and the Cash Ratio is 0.53. Considering the valuation of this stock, the price to sales ratio is 17.98.
Transactions by insiders
Recent insider trading involved JENSEN MICHAEL WOLFF, Officer, that happened on Dec 04 ’25 when 10000.0 shares were purchased. CEO, Jan Moller Mikkelsen completed a deal on Dec 02 ’25 to buy 100000.0 shares. Meanwhile, Officer SPROGOE KENNETT bought 10000.0 shares on Dec 02 ’25.
